애드바이오텍

179530KOSDAQ의약품 제조업

47.5 / 100

Reference Date: 2026-06-10

Financial Score9.0 / 40

News Sentiment17.5 / 25

Momentum6.0 / 20

Disclosure15.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 16.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

AdvaTek is a biotech company developing eco-friendly products for livestock, aquaculture, and human use through technologies like IgY immune yolk antibodies, VHH nanobody antibodies, and microbial agents. Its IgY technology offers high titer and thermal stability, while VHH nanobodies provide strong tissue penetration and easy mass production, positioning them as promising alternatives to antibiotics and vaccines.

Number of Employees

64people

Average Salary

42.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

3.40Industry Average 0.890.0Point

3.8x industry avg (risky)

ROE

-40.31Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

25.03Industry Average 12.430.0Point

2.0x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲14.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -70.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 70

Positive
애드바이오텍, 133억원 규모 유상증자 납입 완료…지배구조 개편
애드바이오텍의 대규모 유상증자 완료로 자금 확보 성공, 지배구조 개편 및 사업 확장에 긍정적 영향 기대.
Neutral
애드바이오텍, 최대주주 대상 30억원 규모 CB 발행 결정
애드바이오텍이 CB 발행 결정을 공시했으나, 구체적인 재무 영향은 명시되지 않았다.

Detailed Momentum

52-week position3.0Point

52w lower range (30%)

Current 2,340Won52-week high 4,58552-week low 1,350

1-month return0.0Point

1m -16.13% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

20 totalPositive 3Neutral 17Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-05
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Positive[기재정정]주요사항보고서(유상증자결정)2026-06-04
Neutral증권발행결과(자율공시)2026-06-04
Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-06-04